Sivik Global Healthcare LLC bought a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 20,000 shares of the medical research company’s stock, valued at approximately $1,873,000.

Several other institutional investors have also recently made changes to their positions in DGX. APG Asset Management N.V. increased its position in shares of Quest Diagnostics by 156.0% during the 3rd quarter. APG Asset Management N.V. now owns 2,683,901 shares of the medical research company’s stock worth $251,320,000 after purchasing an additional 1,635,700 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Quest Diagnostics by 9,350.4% during the 2nd quarter. Janus Henderson Group PLC now owns 1,451,774 shares of the medical research company’s stock worth $161,379,000 after purchasing an additional 1,436,412 shares in the last quarter. AJO LP increased its position in shares of Quest Diagnostics by 137.9% during the 2nd quarter. AJO LP now owns 2,134,245 shares of the medical research company’s stock worth $237,243,000 after purchasing an additional 1,237,021 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its position in shares of Quest Diagnostics by 316.2% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 1,043,889 shares of the medical research company’s stock worth $116,035,000 after purchasing an additional 793,085 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Quest Diagnostics by 3.9% during the 2nd quarter. Vanguard Group Inc. now owns 14,029,322 shares of the medical research company’s stock worth $1,559,500,000 after purchasing an additional 525,200 shares in the last quarter. Institutional investors and hedge funds own 88.52% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “20,000 Shares in Quest Diagnostics Incorporated (DGX) Purchased by Sivik Global Healthcare LLC” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/20000-shares-in-quest-diagnostics-incorporated-dgx-purchased-by-sivik-global-healthcare-llc/1724017.html.

In other news, Chairman Stephen H. Rusckowski sold 59,235 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $108.16, for a total value of $6,406,857.60. Following the transaction, the chairman now owns 220,049 shares of the company’s stock, valued at approximately $23,800,499.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel Stanzione sold 3,803 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $108.01, for a total transaction of $410,762.03. Following the completion of the transaction, the director now directly owns 35,359 shares in the company, valued at approximately $3,819,125.59. The disclosure for this sale can be found here. Insiders sold a total of 160,396 shares of company stock worth $17,343,852 in the last ninety days. Insiders own 1.75% of the company’s stock.

DGX has been the subject of several research reports. Wells Fargo & Company initiated coverage on shares of Quest Diagnostics in a research report on Thursday, October 12th. They issued a “market perform” rating and a $88.00 price objective for the company. Raymond James Financial, Inc. restated a “market perform” rating on shares of Quest Diagnostics in a research report on Monday, September 25th. Goldman Sachs Group, Inc. (The) cut shares of Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and lowered their price objective for the company from $121.00 to $113.00 in a research report on Tuesday, October 10th. KeyCorp restated a “hold” rating on shares of Quest Diagnostics in a research report on Friday, October 27th. Finally, Credit Suisse Group lowered their price objective on shares of Quest Diagnostics from $110.00 to $99.00 and set a “neutral” rating for the company in a research report on Thursday, September 28th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $106.18.

Shares of Quest Diagnostics Incorporated (NYSE DGX) traded up $0.06 during midday trading on Friday, hitting $92.52. 1,476,400 shares of the stock traded hands, compared to its average volume of 993,860. The company has a market cap of $12,610.42, a price-to-earnings ratio of 16.58, a PEG ratio of 1.93 and a beta of 0.59. The company has a quick ratio of 1.37, a current ratio of 1.47 and a debt-to-equity ratio of 0.78. Quest Diagnostics Incorporated has a one year low of $86.11 and a one year high of $112.96.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.04. The company had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.92 billion. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.53%. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.37 EPS. equities research analysts expect that Quest Diagnostics Incorporated will post 5.65 EPS for the current year.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.